Relapsed/refractory classical Hodgkin lymphoma effectively treated with low-dose decitabine plus tislelizumab: A case report

Table 1 The entire treatment process after the diagnosis

Time of therapy	Treatment	Best efficacy	PFS (mo)
November 2014	ABVD × 6 cycles	CR	16
March 2016	AVD × 1 cycle	Unknown	-
September 2016	AVD × 1 cycle	Unknown	-
October 2016	GVD × 4 cycles	PD	4.8
October 2017	GVD × 6 cycles	SD	8.8
July 2018	ESHAP × 1 cycle	PD	0.9
October 2018	AK105 × 9 cycles	PR	3.5
July 2019	IBI188 × 16 wk	SD	3.6
November 2019	DICE × 2 cycles	PD	1.3
February 2020	F0002-ADC × 1 cycle	PD	0.6
March 2020	Decitabine plus tislelizumab	PR	11.5

PFS: Progression-free survival; CR: Complete remission; PR: Partial remission; PD: Progression disease; SD: Stable disease; ABVD: Doxorubicin, bleomycin, vinblastine, and dacarbazine; AVD: Doxorubicin, vinblastine, and dacarbazine; GVD: Gemcitabine, vinorelbine, liposomal doxorubicin; ESHAP: Etoposide, methylprednisolone, high-dose cytarabine, and cisplatin; DICE: Dexamethasone, ifosfamide, cisplatin, and etoposide.